Mizuho Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating

Futu News14:32 · Ratings

Crispr Therapeutics AG (CRSP) Gets a Buy From Mizuho Securities

TipRanks13:59 · Ratings

Editas Downgraded to Market Perform by Raymond James

Seeking Alpha03:16

Earnings Week Ahead: O, PLTR, QCOM, SQ, AMC, PARA, LCID, RIVN, WBD, and More

Seeking AlphaNov 4 13:47

Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers

Yahoo FinanceNov 2 22:00

Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500

BenzingaNov 1 03:23